Enlivex develops Allocetra, a therapy for knee osteoarthritis, and holds RAIN tokens in its treasury. ENLV reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 3 | HC Wainwright & Co. | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in ENLV in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENLV is in one of them and how their past ENLV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ENLV in an article yet. Here's the latest on the wider market.
About Enlivex
Enlivex is a drug development company based in Tel Aviv. It is developing Allocetra, a therapy designed to rebalance the immune system, and is testing it as a possible treatment for knee osteoarthritis, a joint condition linked to aging. The company also holds a treasury of RAIN, the governance token of a decentralized prediction markets platform built on the Arbitrum network.
- Headquarters
- Tel Aviv